Jefferies Positive on Amarin's (AMRN) AMR101 New Chemical Entity Prospects

Earlier, analysts at Jefferies commented on Amarin Corporation (NASDAQ: AMRN) after reviewing Lovaza FDA approval documents.

The firm comments, "In our review of Lovaza FDA approval documents, we learned that the FDA originally denied the Lovaza sponsors their request to use EPA-DHA as the generic name for Lovaza, and instead decided that Lovaza was best described as “3-omega acid ethyl esters.” This gives us incrementally higher confidence in AMRN’s ability to carve out EPA as a distinct active moiety and argue for 5 years of new chemical entity exclusivity for AMR101."

Shares of Amarin have been on a wild ride today related to an inadvertent post about FDA approval for AMR101.

The firm maintained their Buy rating price target of $26.00

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Upgrades Belimo Holding AG (BEAN:SW) (BLHWF) to Buy
• National Bank Financial Upgrades Tidewater Midstream and Infrastructure Ltd. (TWM:CN) (TWMIF) to Outperform
• PhillipCapital Starts 99 Speed Mart (99SMART:MK) at Buy (1)